362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis

• Emmett Schmidt,
• Jonathan Thompson,
• Michael Chisamore,
• James Spicer,
• Åslaug Helland,
• Edurne Arriola,
• Manuel Dómine Gomez,
• Jose Manuel Trigo Perez,
• Ana Laura Ortega Granados,
• Noelly Madeleine,
• Austin Rayford,
• Katherine Lorens,
• Abdul Siddiqui,
• Hani Gabra,
• Jaya Nautiyal,
• David Micklem,
• James Lorens

Affiliations

Emmett Schmidt

Aff145 grid.417993.10000000122600793Merck & Co., Inc. Kenilworth NJ USA

Jonathan Thompson

Aff7 0000 0001 2111 8460grid.30760.32Medical College of Wisconsin 8701 W Watertown Plank Rd 53226 Milwaukee WI USA

Michael Chisamore

2Merch and Co., Inc., Rahway, NJ, USA

James Spicer

1King’s College London, Guy’s Hospital, London, UK

Åslaug Helland

2Oslo University Hospital, Oslo, Norway

Edurne Arriola

4Hospital del Mar, Barcelona, Spain

Manuel Dómine Gomez

5Hospital Universitario Fundación Jiménez, Madrid, Spain

Jose Manuel Trigo Perez

6Hospital Virgen de la Victoria, Málaga, Spain

Ana Laura Ortega Granados

9Complejo Hospitalario de Jaén, Jaén, Spain

Noelly Madeleine

12BerGenBio ASA, Bergen, Norway

Austin Rayford

12BerGenBio ASA, Bergen, Norway

Katherine Lorens

12BerGenBio ASA, Bergen, Norway

Abdul Siddiqui

12BerGenBio ASA, Bergen, Norway

Hani Gabra

12BerGenBio ASA, Bergen, Norway

Jaya Nautiyal

12BerGenBio ASA, Bergen, Norway

David Micklem

12BerGenBio ASA, Bergen, Norway

James Lorens

12BerGenBio ASA, Bergen, Norway